Maria Martinez-Lage

Maria Martinez-Lage

Auto-generated profile, based on publicly available information

Maria Martinez-Lage

Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DODonald M. O’rourke
Donald M. O’rourke
MNMacLean Pancoast Nasrallah
MacLean Pancoast Nasrallah
ADArati Desai
Arati Desai
Jan Joseph MelenhorstJan Joseph Melenhorst
Jan Joseph Melenhorst
KMKeith Mansfield
Keith Mansfield
MMMarcela V. Maus
Marcela V. Maus
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.

1 December 2010 in Neuron
Verified
Journal Article
Closed access
JJJanel O. Johnson
Janel O. Johnson
JESSICA MANDRIOLIJESSICA MANDRIOLI
JESSICA MANDRIOLI
MBMichael Benatar
Michael Benatar
YAYevgeniya Abramzon
Yevgeniya Abramzon
VDVivianna M. Van Deerlin
Vivianna M. Van Deerlin
BTBryan J. Traynor
Bryan J. Traynor

20 April 2018 in Science
Verified
Journal Article
Closed access
PDF file
MFMariella G. Filbin
Mariella G. Filbin
ITItay Tirosh
Itay Tirosh
VHVolker Hovestadt
Volker Hovestadt
MSMcKenzie L. Shaw
McKenzie L. Shaw
LELeah E. Escalante
Leah E. Escalante
MSMario L. Suvà
Mario L. Suvà
The cellular composition of H3K27M gliomas: Diffuse midline gliomas with histone H3 lysine27-to-methionine mutations (H3K27M-glioma) are an aggressive type of childhood cancer with few options for treatment. Filbin et al. used a single-cell sequencing approach to study the oncogenic programs, genetics, and cellular hierarchies of H3K27M-glioma. Tumors were mainly composed of cells resembling oligodendrocyte precursor cells, whereas differentiated malignant cells were a smaller fraction. In comparison with other gliomas, these cancers had distinct oncogenic programs and stem cell–like profiles that contributed to their stable tumor-propagating potential. The analysis also identified a lineage-specific marker that may be useful in developing therapies. Science , this issue p. 331

1 May 2008 in The Lancet Neurology
Verified
Journal Article
Closed access
VDVivianna M Van Deerlin
Vivianna M Van Deerlin
JLJames B Leverenz
James B Leverenz
LBLynn M Bekris
Lynn M Bekris
TBThomas D Bird
Thomas D Bird
WYWuxing Yuan
Wuxing Yuan
CYChang-En Yu
Chang-En Yu

14 February 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
VDVivianna M Van Deerlin
Vivianna M Van Deerlin
PSPatrick M A Sleiman
Patrick M A Sleiman
MMMaria Martinez-Lage
Maria Martinez-Lage
ACAlice Chen-Plotkin
Alice Chen-Plotkin
LWLi-San Wang
Li-San Wang
VLVirginia M-Y Lee
Virginia M-Y Lee
Vivianna Van Deerlin and colleagues report that common variants at 7p21 are associated with a subtype of frontotemporal lobar degeneration marked by TDP-43 inclusions. They further show that the risk alleles are associated with elevated brain expression of TMEM106B, which resides at the peak of association on 7p21. Frontotemporal lobar degeneration (FTLD) is the second most common cause of presenile dementia. The predominant neuropathology is FTLD with TAR DNA-binding protein (TDP-43) inclusions (FTLD-TDP)1. FTLD-TDP is frequently familial, resulting from mutations in GRN (which encodes progranulin). We assembled an international collaboration to identify susceptibility loci for FTLD-TDP through a genome-wide association study of 515 individuals with FTLD-TDP. We found that FTLD-TDP associates with multiple SNPs mapping to a single linkage disequilibrium block on 7p21 that contains TMEM106B. Three SNPs retained genome-wide significance following Bonferroni correction (top SNP rs1990622, P = 1.08 × 10−11; odds ratio, minor allele (C) 0.61, 95% CI 0.53–0.71). The association replicated in 89 FTLD-TDP cases (rs1990622; P = 2 × 10−4). TMEM106B variants may confer risk of FTLD-TDP by increasing TMEM106B expression. TMEM106B variants also contribute to genetic risk for FTLD-TDP in individuals with mutations in GRN. Our data implicate variants in TMEM106B as a strong risk factor for FTLD-TDP, suggesting an underlying pathogenic mechanism.

12 January 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PBPriscilla K Brastianos
Priscilla K Brastianos
ATAmaro Taylor-Weiner
Amaro Taylor-Weiner
PMPeter E Manley
Peter E Manley
RJRobert T Jones
Robert T Jones
DDDora Dias-Santagata
Dora Dias-Santagata
SSSandro Santagata
Sandro Santagata
Sandro Santagata, Gad Getz and colleagues report the discovery of a recurrent mutation in the oncogene BRAF in papillary craniopharyngiomas that does not occur in the histologically related adamantinomatous form. Their results have the potential to aid in diagnosis and treatment of these intracranial tumors. Craniopharyngiomas are epithelial tumors that typically arise in the suprasellar region of the brain1. Patients experience substantial clinical sequelae from both extension of the tumors and therapeutic interventions that damage the optic chiasm, the pituitary stalk and the hypothalamic area2,3,4. Using whole-exome sequencing, we identified mutations in CTNNB1 (β-catenin) in nearly all adamantinomatous craniopharyngiomas examined (11/12, 92%) and recurrent mutations in BRAF (resulting in p.Val600Glu) in all papillary craniopharyngiomas (3/3, 100%). Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors). The CTNNB1 and BRAF mutations were clonal in each tumor subtype, and we detected no other recurrent mutations or genomic aberrations in either subtype. Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms.